| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | -0.047 | 0.1 |
| mRNA | BMS-754807 | FIMM | pan-cancer | AAC | -0.2 | 0.1 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.1 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.071 | 0.1 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.1 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.045 | 0.1 |
| mRNA | S-Trityl-L-cysteine | FIMM | pan-cancer | AAC | 0.26 | 0.1 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | PD-0332991 | FIMM | pan-cancer | AAC | -0.24 | 0.1 |